Hussman Strategic Advisors Inc. Takes Position in Tempus AI, Inc. $TEM

Hussman Strategic Advisors Inc. bought a new position in shares of Tempus AI, Inc. (NASDAQ:TEM) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 21,000 shares of the company’s stock, valued at approximately $1,695,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Global Retirement Partners LLC raised its stake in shares of Tempus AI by 29.5% during the 3rd quarter. Global Retirement Partners LLC now owns 733 shares of the company’s stock valued at $59,000 after buying an additional 167 shares during the last quarter. China Universal Asset Management Co. Ltd. grew its holdings in Tempus AI by 0.7% during the second quarter. China Universal Asset Management Co. Ltd. now owns 33,757 shares of the company’s stock worth $2,145,000 after acquiring an additional 226 shares during the period. Wealth Enhancement Advisory Services LLC raised its position in Tempus AI by 2.6% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 9,929 shares of the company’s stock valued at $801,000 after acquiring an additional 248 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in Tempus AI by 6.1% in the second quarter. PNC Financial Services Group Inc. now owns 5,003 shares of the company’s stock valued at $318,000 after acquiring an additional 287 shares during the period. Finally, PFG Investments LLC boosted its position in Tempus AI by 8.5% in the 3rd quarter. PFG Investments LLC now owns 3,830 shares of the company’s stock worth $309,000 after purchasing an additional 300 shares in the last quarter. 24.22% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

TEM has been the subject of several recent research reports. Canaccord Genuity Group cut their target price on shares of Tempus AI from $95.00 to $80.00 and set a “buy” rating for the company in a report on Monday, December 22nd. Needham & Company LLC upped their price objective on shares of Tempus AI from $70.00 to $100.00 and gave the stock a “buy” rating in a research report on Wednesday, November 5th. TD Cowen lowered shares of Tempus AI from a “buy” rating to a “hold” rating in a research note on Tuesday, October 21st. Morgan Stanley lifted their price target on Tempus AI from $80.00 to $85.00 and gave the company an “overweight” rating in a research note on Monday, December 1st. Finally, HC Wainwright reduced their price target on Tempus AI from $98.00 to $89.00 and set a “buy” rating for the company in a report on Friday, November 7th. Six investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Tempus AI has a consensus rating of “Hold” and a consensus target price of $87.20.

Insider Transactions at Tempus AI

In other Tempus AI news, EVP Andrew Polovin sold 12,874 shares of the firm’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $75.00, for a total value of $965,550.00. Following the transaction, the executive vice president owned 107,590 shares in the company, valued at approximately $8,069,250. This trade represents a 10.69% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Ryan Fukushima sold 10,099 shares of Tempus AI stock in a transaction on Tuesday, November 18th. The stock was sold at an average price of $65.54, for a total transaction of $661,888.46. Following the sale, the chief operating officer directly owned 829,081 shares in the company, valued at approximately $54,337,968.74. This trade represents a 1.20% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 600,332 shares of company stock worth $41,554,949. 26.27% of the stock is owned by insiders.

Tempus AI Stock Down 3.4%

Shares of NASDAQ TEM opened at $64.57 on Thursday. The company’s 50-day simple moving average is $68.81 and its 200-day simple moving average is $73.95. Tempus AI, Inc. has a 52-week low of $36.22 and a 52-week high of $104.32. The firm has a market cap of $11.49 billion, a price-to-earnings ratio of -54.26 and a beta of 5.22. The company has a quick ratio of 3.12, a current ratio of 3.28 and a debt-to-equity ratio of 2.45.

Tempus AI (NASDAQ:TEM) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.11) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.05. The firm had revenue of $334.21 million during the quarter, compared to the consensus estimate of $328.89 million. Tempus AI had a negative net margin of 18.45% and a negative return on equity of 73.21%. The company’s revenue for the quarter was up 84.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.46) EPS. Equities analysts predict that Tempus AI, Inc. will post -6.15 EPS for the current fiscal year.

Tempus AI Company Profile

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.